Regent Pacific Announces 2016 Interim Financial Results
Substantial Increase in Profits and Shareholder Equity

HIGHLIGHTS

Key financial results

- Profit attributable to shareholders for the six months ended 30 June 2016 surged 132 fold to US$15.96 million(2015: US$0.12 million)
- Shareholders' equity and NAV per share increased 412.55% and 2.85% respectively against 31 December 2015, to US$200.32 million and 89.47 HK cents per share
- Earnings per share increased nearly 32 fold to US cents 1.310
- Debt free, with over US$12 million in cash, listed and unlisted securities

Key developments

- Completed acquisition of UK specialty pharmaceutical company Plethora
- Manufacturing activities of PSD502® commenced in early August 2016, paving the way of its full scale commercial launch in the United Kingdom around November 2016, and with continental Europe in April 2017
- Approximately GBP 1 million of additional investments into The Diabetic Boot Company Limited was completed, increasing stake to 22.0%
- Realised US$3.95 million in cash from the disposals of our remaining interests in Endeavour and Binary during the period
- The Group continues to seek new strategic and value-led investments in the healthcare and life sciences sectors

(30 August 2016, Hong Kong) – Regent Pacific Group Limited ("**Regent Pacific**" or the "**Company**" and together with its subsidiaries, the "**Group**"; HKSE stock code: 00575), a specialist healthcare and life sciences investment group today announces unaudited financial results for the six months ended 30 June 2016 ("**the period**").

Profit attributable to shareholders surged 132 fold to US$15.96 million (2015: US$0.12 million). The bulk of this increase being attributable to the US$31.69 million bargain purchase on the acquisition of Plethora Solutions Holding plc ("**Plethora**"), (which is the gain generated from the fair value of the consideration shares that the Company issued being lower than the fair value of entire issued and to be issued ordinary share capital of Plethora (other than Plethora's shares held by the Group)), and a marked-to-market gain of US$2.95 million in respect of the Group's equity portfolio of financial assets at fair value through profit or loss, while being offset by non-cash items from the loss on the deemed disposal of the Group's pre-existing stake in Plethora of US$5.81 million and an amortisation charge of US$8.75 million on the intangible asset, PSD502®.

Shareholders' equity and net asset value ("**NAV**") per share jumped 412.55% to US$200.32 million and 2.85% to HK cents 89.47 (US cents 11.53) respectively from US$39.08 million and HK cents 86.90 as at 31 December 2015. The significant increase in shareholders' equity is mainly attributable to the acquisition of Plethora through issuing new shares as consideration of approximately US$143.07 million. Earnings per share attributable to shareholders during the period increased 35 fold to US cents 1.31 from US cent 0.04 for the same period last year.

Jamie Gibson, CEO of Regent Pacific said, *"Regent Pacific delivered a solid performance for the first six months in 2016. The acquisition of Plethora not only strengthened our asset base, it was also an important step in the establishment of Regent Pacific as a specialist healthcare and life sciences investment group.*

*Moreover, we are very delighted with the progress in the commercialization of PSD502®. With manufacturing activities already commenced that means long suffering PE patients will have a prescription remedy within months. The launch will deliver an important initial stage payment from our partner Recordati S.p.A. ("**Recordati**"), and a steady stream of recurring cash flow for the Group will follow in the years to come."*

Encouraging progress in healthcare portfolio building and product commercialization

Plethora

Regent Pacific has successfully completed the acquisition of Plethora following all requisite approvals duly obtained for the Group's recommended share exchange offer launched to the UK pharmaceutical company in December 2015. The scheme of arrangement became effective on 9 March 2016, rendering Plethora a wholly-owned subsidiary of the Group as of that date. The Group has made a bargain purchase gain of US$31.69 million on this transaction, which has contributed to the Group in the first half of 2016.

During the period, the development activities relating to the reduced dose can (not less than 12 doses) were completed, and the reduced version has also successfully obtained European Medicines Agency's ("**EMA**") approval on 17 May of this year. Manufacturing activities for the product with partner Pharmaserve North West Limited has already commenced in early August.

Diabetic Boot

During the six months ended 30 June 2016, the Group made a commitment to increase its strategic position in Diabetic Boot in three tranches. The first tranche was completed in 11 May 2016, which increased the Group's interest in the latter to approximately 23.04%. The Group's shareholding was later reduced to 22.00% due to Diabetic Boot's issuance of new shares to third party investors in respect of the first tranche subscription.

Furthermore, Diabetic Boot has made substantial progress in launching its principal product "PulseFlowDF" for the treatment of diabetic foot ulcers. Commercial manufacturing has already commenced in UK with first sales taking place in August 2016 to the Veterans Administration Hospitals in the US. Diabetic Boot has received Durable Medical Equipment, Prosthetics, Orthotics and Supplies accreditation in all 50 states and the District of Columbia. Commercialisation in the US will be done through a wholly-owned subsidiary with its own sales force, and through distributors in other jurisdictions, with the initial target being the Veterans Administration Hospitals.

Active disposal of legacy investments to refocus in healthcare and life sciences

As the Group seeks to refocus its strategy to the healthcare and life sciences sectors, it continued to evaluate its existing investments in the natural resources sector around their natural life cycle, with a view to further execute its strategy of divesting non-core assets and investments.

Disposals during the period include the Group's selling of its remaining interest in Binary Limited ("**Binary**") for a consideration of US$1.15 million in cash. The deal successfully closed on 13 June 2016 and Binary was sold for an aggregate of US$16.15 million, representing a "cash-on-cash" return of 13.02 times.

In addition, the Group successfully disposed of its entire interest in Endeavour Mining Corporation ("**Endeavour**") through a series of on-market transactions with completion reached on 17 February 2016, for an aggregate consideration of approximately US$2.80 million in cash, thereby realizing a gain on disposal of approximately US$0.32 million for the period.

For resources investments still on hold, Regent Pacific continued to monitor and maintain actively its strategic position in these companies as it looks to deliver favorable returns from these investments. The Group continues to hold a 33.63% stake in Venturex Resources Limited, which for the six months ended 30 June 2016 has registered a marked-to-market gain of approximately 43.02%. The Group's 7.53% stake in Condor Gold plc also posted a marked-to-market gain of approximately 152.55% for the six months ended 30 June 2016.

Other corporate developments

During the period, the Group has implemented changes to its capital structure by way of a share consolidation on a 10 for 1 basis, which has taken effect on 10 June 2016. In addition, a proposed capital reduction has also been approved by shareholders at the extraordinary general meeting held on 19 August 2016, but still subject to the approval by the Grand Court of the Cayman Islands, which will result in the par value of the issued and unissued shares of the Group reducing from US$0.10 each to US$0.01 each, which in turn lower the authorised and issued share capital by 90 per cent.

Outlook

"For the latter half of 2016, the Group's healthcare and life sciences investments will remain to be our core focus. They are far less sensitive to macro volatilities and the Group remains excited about the prospects of these investments, and we look forward to boost the value they will bring to our shareholders," Jamie Gibson said.

Plethora

Recordati is set to undertake a full scale commercial launch for PSD502® later this year, first starting in the United Kingdom around November 2016 and continental Europe to follow in April 2017. The commercial launch in Germany, Italy, Spain, France and Portugal is expected to each trigger first launch payments from Recordati, with other sales-based milestone payments and royalty payments thereafter as it build sales to create a steady income stream to the Group. Discussions with new potential commercial partners to out-license PSD502® in the regions of Asia Pacific, Middle East, Latin America, North America and Sub-Sahara Africa will continue.

In the US, the Group is anticipating to start Phase III clinical study for the NDA for PSD502® in Q4 2016, with application filling to the FDA expected in Q2 2017. The FDA will respond to the dossier within a 10 month timescale as required by regulatory guidelines, which will facilitate approval by Q2 2018 and commercial launch in the region shortly thereafter.

Diabetic Boot

Regent Pacific will continue to follow closely on the development progress of Diabetic Boot and upon satisfaction of the medical device company's various operational and commercial milestones, the Group will enter into the second and third tranche of funding which could potentially bring its stake in Diabetic Boot up to 31.80%, with a total consideration for the three tranches of up to approximately GBP 3 million (or approximately US$4.2 million).

Conclusion

Jamie Gibson concluded, "*Going forward, Regent Pacific will focus on integrating Plethora into the Group, as we pursue the successful launching of PSD502® as quickly as possible – not only in Europe, but also in the remaining key markets of North America, Middle East and Asia Pacific regions. The latter, in particular, will be a key component as the Group's Hong Kong office will provide an excellent base from which to manage the controlled launch of the product following receipt of relevant regulatory approvals. We are confident that Regent Pacific will be able to generate significant shareholder value over time while delivering benefits to patients around the world*."

- END -

About Regent Pacific

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare and life sciences sectors. Its wholly-owned subsidiary, Plethora Solutions Holdings Plc, is a specialty pharmaceutical company whose core product PSD502® is the first EU approved topical prescription treatment for Premature Ejaculation, set to launch in the UK around November 2016 and subsequently in Italy, Spain, France, Germany, Portugal, Czech Republic, Slovakia, Poland, Ireland, Romania and Greece, the rest of Europe, Russia, CIS and certain countries of North Africa. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 19 years of financial reporting since its IPO. For further information, please contact:

For further information, please contact:

Finsbury

Ben Richardson
t : +852 3166 9878
e : ben.richardson@finsbury.com

Karen Yu
t : +852 3166 9866
e : Karen.yu@finsbury.com

Alastair Hetherington
t : +44 207 0736336
e: alastair.hetherington@finsbury.com